Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:33:43.277Z.
Calculation as of: 2026-10-06T15:33:43.277Z.
Quote observation: 2026-10-06T15:31:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$265.45M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.17M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.39M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.97M
EV/EBIT Ratio
N/A
TTM Avg
162862.62x
3Y Avg
112489.16x
5Y Avg
112489.16x
Market Cap
$268.20M
EV/EBIT Ratio
N/A
TTM Avg
5.32x
3Y Avg
26.78x
5Y Avg
44.78x
Market Cap
$271.23M
EV/EBIT Ratio
N/A
TTM Avg
11.31x
3Y Avg
11.31x
5Y Avg
15.93x
Market Cap
$258.56M
EV/EBIT Ratio
N/A
TTM Avg
6.80x
3Y Avg
6.80x
5Y Avg
39.86x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $265.45M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $267.17M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.39M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | N/A | 162862.62x | 112489.16x | 112489.16x |
| OraSure Technologies, Inc. (OSUR)vs › | $268.20M | N/A | 5.32x | 26.78x | 44.78x |
| AC Immune S.A. (ACIU)vs › | $260.03M | N/A | 17.57x | 14.15x | 16.75x |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.23M | N/A | 11.31x | 11.31x | 15.93x |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.56M | N/A | 6.80x | 6.80x | 39.86x |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | N/A | 15.89x | 15.15x | 15.15x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
